Nuclear Medicine

• Our staff
   

  Nuclear Medicine

  Director

  Francesco Ceci

  • Radiometabolic Therapy Unit

    Director Chiara Maria Grana

  Staff Nuclear Medicine

  • • Physician Marzia Colandrea
    • Physician Silvia Lidia Fracassi
  • • Physician Laura Gilardi
    • Physician Paola Anna Rocca
  • • Physician Laura Lavinia Travaini
• Clinical trials

  IEO S685/112

  A multicentre, stratified, open, randomized, comparator-controlled, parallelgroup phase III study comparing treatment with 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in patients with inoperable, progressive, somatostatin receptor positive, midgut carcinoid tumours

   

  IEO S738

  A phase 3, open-label, multicenter, randomized study of sequential Zevalin (ibritumomab tiuxetan) versus observation in patients at least 60 years of age with newly diagnosed diffuse large B-cell lymphoma in PET-negative complete remission after R-CHOP or R-CHOP-like therapy

   

  IEO S 724/512

  A randomized, open-label, multicentre, two-arm phase III comparative study assessing the role of mediastinal radiotherapy after Rituximab containing chemotherapy regimens to patients with newly diagnosed Primary Mediastinal Large B-Cell Lymphoma (PMLBCL)

   

• publications

  "Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study."

  Veronesi U, Viale G, Paganelli G, Zurrida S, Luini A, Galimberti V, Veronesi P, Intra M, Maisonneuve P, Zucca F, Gatti G, Mazzarol G, De Cicco C, Vezzoli D.

  Ann Surg. 2010 Apr;251(4):595-600. doi: 10.1097/SLA.0b013e3181c0e92a.

   

  "Is there a role for sentinel node biopsy in early N0 tongue tumors?"

  Chiesa F, Mauri S, Grana C, Tradati N, Calabrese L, Ansarin M, Mazzarol G, Paganelli G.

  Surgery. 2000 Jul;128(1):16-21.

   

  "Sentinel node biopsy in early vulvar cancer."

  De Cicco C, Sideri M, Bartolomei M, Grana C, Cremonesi M, Fiorenza M, Maggioni A, Bocciolone L, Mangioni C, Colombo N, Paganelli G.

  Br J Cancer. 2000 Jan;82(2):295-9.

   

  "Preoperative FDG PET/CT in breast cancer patients: where are we going?"

  Gilardi L, De Cicco C, Paganelli G.

  Eur J Nucl Med Mol Imaging. 2012 Nov;39(11):1667-9. doi: 10.1007/s00259-012-2245-2. No abstract available.

   

  "Yttrium-labelled peptides for therapy of NET."

  Bodei L, Cremonesi M, Grana CM, Chinol M, Baio SM, Severi S, Paganelli G.

  Eur J Nucl Med Mol Imaging. 2012 Feb;39 Suppl 1:S93-102. doi: 10.1007/s00259-011-2002-y. Review.

   

  "Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study."

  Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, Bartolomei M, Lombardo D, Ferrari ME, Sansovini M, Chinol M, Paganelli G.

  Eur J Nucl Med Mol Imaging. 2011 Dec;38(12):2125-35. doi: 10.1007/s00259-011-1902-1. Epub 2011 Sep 3

   

  "Intraoperative avidination for radionuclide treatment as a radiotherapy boost in breast cancer: results of a phase II study with (90)Y-labeled biotin."

  Paganelli G, De Cicco C, Ferrari ME, Carbone G, Pagani G, Leonardi MC, Cremonesi M, Ferrari A, Pacifici M, Di Dia A, De Santis R, Galimberti V, Luini A, Orecchia R, Zurrida S, Veronesi U.

  Eur J Nucl Med Mol Imaging. 2010 Feb;37(2):203-11. doi: 10.1007/s00259-009-1260-4. Epub 2009 Sep 4.

   

  "Eleven-Year Experience with the Avidin-Biotin Pretargeting System in Glioblastoma: Toxicity, Efficacy and Survival"

  Grana CM, Chinol M, De Cicco C, Bartolomei M, Cremonesi M, Bodei L, Rocca PA, Pacifici M, Tiberini S, Baio SM, Broggi G, Severi S and Paganelli G.

  The Open Nuclear Medicine Journal. 2012; 4:14-20 - 1876-388X/12 2012 Bentham Open Access. 

   

  "Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study."

  Grana C, Chinol M, Robertson C, Mazzetta C, Bartolomei M, De Cicco C, Fiorenza M, Gatti M, Caliceti P, Paganelli G.

  Br J Cancer. 2002 Jan 21;86(2):207-12.

   

  "Radioimmunotherapy in advanced ovarian cancer: is there a role for pre-targeting with (90)Y-biotin?"

  Grana C, Bartolomei M, Handkiewicz D, Rocca P, Bodei L, Colombo N, Chinol M, Mangioni C, Malavasi F, Paganelli G.

  Gynecol Oncol. 2004 Jun;93(3):691-8.

   

  "Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients."

  Sauer S, Erba PA, Petrini M, Menrad A, Giovannoni L, Grana C, Hirsch B, Zardi L, Paganelli G, Mariani G, Neri D, Dürkop H, Menssen HD.

  Blood. 2009 Mar 5;113(10):2265-74. doi: 10.1182/blood-2008-06-160416. Epub 2009 Jan 8.

   

  "High activity 90Y-ibritumomab tiuxetan (Zevalin) with peripheral blood progenitor cells support in patients with refractory/resistant B-cell non-Hodgkin lymphomas."

  Ferrucci PF, Vanazzi A, Grana CM, Cremonesi M, Bartolomei M, Chinol M, Ferrari M, Radice D, Papi S, Martinelli G, Paganelli G.

  Br J Haematol. 2007 Nov;139(4):590-9.